> ## Content Index
> Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# CDC Recommends Updated XBB.1.5 COVID-19 Vaccines for Everyone 6 Months and Older After 13-1 Advisory Vote
- URL: https://www.theamericanquorum.com/taq-historical-2023-09-16-healthcare/
- Published: 2023-09-17T03:59:00.000Z
- Updated: 2023-09-17T03:59:00.000Z
- Description: CDC recommended updated monovalent XBB.1.5 COVID-19 vaccination for everyone 6 months and older after FDA cleared Pfizer-BioNTech and Moderna formulations for the 2023–2024 season.
- Author: Kenneth R. Deans Jr.
- Tags: Healthcare, #Import 2026-09-01 05:56

The Centers for Disease Control and Prevention this week recommended that everyone 6 months and older receive an updated COVID-19 vaccine for the fall and winter season, establishing a broad national policy after federal regulators cleared new Pfizer-BioNTech and Moderna formulations designed around the Omicron XBB.1.5 lineage.

The [CDC recommendation](https://www.cdc.gov/media/releases/2023/p0912-COVID-19-Vaccine.html?ref=theamericanquorum.com), issued September 12 after the agency’s Advisory Committee on Immunization Practices voted 13-1, means the updated vaccines can move into routine clinical use as manufacturers begin shipping doses to pharmacies, physician offices and other vaccination sites. CDC said vaccination remains the best protection against hospitalization and death and advised eligible people who have not received a COVID-19 vaccine in the past two months to receive the updated product.

## The United States is moving from a bivalent booster to a monovalent seasonal formulation

The Food and Drug Administration acted one day earlier, approving and authorizing updated mRNA vaccines manufactured by Moderna and Pfizer-BioNTech. The [FDA’s September 11 action](https://www.fda.gov/news-events/press-announcements/fda-takes-action-updated-mrna-covid-19-vaccines-better-protect-against-currently-circulating?source=govdelivery) replaced the earlier bivalent formulation with a monovalent component corresponding to XBB.1.5, a lineage selected to more closely match the family of variants circulating in 2023.

For most people age 5 and older, the new policy simplifies vaccination to one updated dose regardless of previous vaccination history, provided enough time has passed since the most recent dose. Younger children have age- and product-specific schedules because their primary series can require multiple doses. People who are moderately or severely immunocompromised may also require additional doses under clinical guidance.

The FDA said both updated mRNA vaccines are approved for people 12 and older and authorized for emergency use in children 6 months through 11 years. As part of the regulatory change, the older bivalent Moderna and Pfizer-BioNTech vaccines are no longer authorized in the United States.

## Manufacturers say the updated shots broaden responses to currently circulating variants

Pfizer and BioNTech said their 2023–2024 formulation is tailored to XBB.1.5 and is intended as a single dose for most people age 5 and older. In the companies’ [September 11 announcement](https://www.pfizer.com/news/press-release/press-release-detail/pfizer-and-biontech-receive-us-fda-approval-2023-2024-covid?ref=theamericanquorum.com), they reported preclinical neutralization activity against XBB.1.5 as well as other Omicron-related lineages including EG.5.1 and BA.2.86\. The companies said they were working with pharmacies, hospitals and clinics to make doses available rapidly.

Moderna likewise said its updated Spikevax formulation contains an XBB.1.5 component and produced immune responses against several circulating variants. The company’s [approval statement](https://news.modernatx.com/news/news-details/2023/Moderna-Receives-U.S.-FDA-Approval-for-Updated-COVID-19-Vaccine/default.aspx?ref=theamericanquorum.com) said doses would begin shipping immediately, with availability expected in pharmacies and care settings within days.

At the September 12 ACIP meeting, Moderna presented safety and immunogenicity data for the updated formulation. A [CDC-hosted presentation](https://stacks.cdc.gov/view/cdc/132893?ref=theamericanquorum.com) from the meeting summarized the company’s evidence for the XBB.1.5 vaccine and formed part of the material advisers considered before voting.

## The broad recommendation reflects continuing risk across age groups

ACIP considered whether the updated vaccine should be recommended universally or targeted primarily to people at greatest risk of severe disease. Older adults, people with certain chronic conditions and immunocompromised patients continue to face the highest risks of hospitalization and death, but healthy children and adults can also experience severe disease, post-COVID conditions and disruptions from infection.

The committee ultimately chose a broad recommendation. That approach preserves a straightforward message and supports access through routine insurance coverage, while leaving clinicians to discuss timing and individual risk with patients. CDC said the updated vaccines are expected to restore protection that declines over time and provide better alignment with the variants currently causing infections and hospitalizations.

The decision also comes as COVID-19 vaccination transitions into a more conventional commercial market. Unlike earlier phases of the pandemic, when the federal government purchased and distributed most doses, manufacturers and private-sector distributors are increasingly responsible for supply. That makes insurance coverage, pharmacy contracting and the federal Bridge Access Program important for people who lack adequate coverage.

## Novavax remains under FDA review as the mRNA vaccines move first

A third updated product, Novavax’s protein-based XBB vaccine, is not yet authorized. In a [September 11 statement](https://ir.novavax.com/press-releases/Novavax-Continues-Progress-Towards-Delivery-of-its-Protein-based-Non-mRNA-XBB-COVID-Vaccine-to-US?ref=theamericanquorum.com), Novavax said doses had arrived in the United States and were positioned for distribution pending FDA and CDC action. The company presented its updated formulation to ACIP on September 12 but remains subject to the separate regulatory process.

The presence of a protein-based alternative could matter for people who prefer or require a non-mRNA option, but the near-term fall campaign begins with the cleared Pfizer-BioNTech and Moderna products. That sequencing reflects regulatory timing rather than a CDC determination that one technology should displace the other.

## The new recommendation creates a clearer fall respiratory-virus strategy

The updated COVID-19 decision arrives alongside expanded prevention options for influenza and respiratory syncytial virus. Adults 60 and older have access to newly approved RSV vaccines under shared clinical decision-making, and infants can be protected through a new long-acting monoclonal antibody. Seasonal influenza vaccination remains broadly recommended.

For health systems, the immediate task is implementation: receiving product, updating electronic order sets, training staff on age-specific schedules, confirming payer coverage and communicating that the 2023–2024 COVID vaccine is not simply another dose of last year’s bivalent booster. The formula has changed, and the older mRNA vaccines have been removed from authorization.

The September 12 vote therefore represents both a scientific and operational reset. Federal regulators selected a formulation intended to better match the current viral landscape, the CDC chose a universal recommendation rather than a risk-restricted one, and manufacturers are shifting supply into ordinary commercial channels. The success of that strategy will now depend on how quickly doses reach patients and whether Americans who have become less inclined to seek repeat COVID vaccination decide the updated formulation is worth receiving before winter.